Tags

Type your tag names separated by a space and hit enter

[Drug therapy in Parkinson's disease].
Ned Tijdschr Geneeskd. 1999 Jan 30; 143(5):234-40.NT

Abstract

Levodopa is still the mainstay of the treatment of Parkinson's disease. Limitations of levodopa therapy have led to development of numerous therapeutic approaches at the level of levodopa/dopamine metabolism, dopamine receptors, dopamine transporter, and other neurotransmitter systems. New insights into the pathophysiology of Parkinson's disease have led to the promising concepts of neuroprotection and neurorestoration. In daily practice therapeutic management of Parkinson's disease is still symptomatic.

Authors+Show Affiliations

Leids Universitair Medisch Centrum, afd. Neurologie, Leiden.No affiliation info available

Pub Type(s)

English Abstract
Historical Article
Journal Article
Review

Language

dut

PubMed ID

10086151

Citation

van Hilten, J J., and R A. Roos. "[Drug Therapy in Parkinson's Disease]." Nederlands Tijdschrift Voor Geneeskunde, vol. 143, no. 5, 1999, pp. 234-40.
van Hilten JJ, Roos RA. [Drug therapy in Parkinson's disease]. Ned Tijdschr Geneeskd. 1999;143(5):234-40.
van Hilten, J. J., & Roos, R. A. (1999). [Drug therapy in Parkinson's disease]. Nederlands Tijdschrift Voor Geneeskunde, 143(5), 234-40.
van Hilten JJ, Roos RA. [Drug Therapy in Parkinson's Disease]. Ned Tijdschr Geneeskd. 1999 Jan 30;143(5):234-40. PubMed PMID: 10086151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Drug therapy in Parkinson's disease]. AU - van Hilten,J J, AU - Roos,R A, PY - 1999/3/23/pubmed PY - 1999/3/23/medline PY - 1999/3/23/entrez SP - 234 EP - 40 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 143 IS - 5 N2 - Levodopa is still the mainstay of the treatment of Parkinson's disease. Limitations of levodopa therapy have led to development of numerous therapeutic approaches at the level of levodopa/dopamine metabolism, dopamine receptors, dopamine transporter, and other neurotransmitter systems. New insights into the pathophysiology of Parkinson's disease have led to the promising concepts of neuroprotection and neurorestoration. In daily practice therapeutic management of Parkinson's disease is still symptomatic. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/10086151/[Drug_therapy_in_Parkinson's_disease]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -